<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04744818</url>
  </required_header>
  <id_info>
    <org_study_id>VINO</org_study_id>
    <nct_id>NCT04744818</nct_id>
  </id_info>
  <brief_title>Effects of Iron Supplementation on Pediatric Vaccine Response</brief_title>
  <acronym>VINO</acronym>
  <official_title>Effects of Iron Supplementation on Pediatric Vaccine Response</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nicole Stoffel</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Jomo Kenyatta University of Agriculture and Technology Kenya</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Karolinka Institute Sweden</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Oxford</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute for Public Health and Environment Netherlands</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Swiss Federal Institute of Technology</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      ID/IDA affects many young children in Africa. Vaccines provide tremendous benefits in LMIC;&#xD;
      however, they currently fail to reach their full potential. We need to better understand the&#xD;
      causes of vaccine failure, in order to develop new strategies to improve vaccine&#xD;
      immunogenicity.&#xD;
&#xD;
      This study will contribute to children's health by: (1) providing updated guidelines to&#xD;
      better define the prevalence of ID/IDA in early infancy, and its safe and effective control&#xD;
      using iron; and (2) providing a new approach to improve response to pediatric vaccines in&#xD;
      LMIC, by ensuring adequate iron status at time of vaccination.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Two major pediatric public health goals in LMIC are increasing immunization effectiveness and&#xD;
      reducing ID/IDA in children. ID/IDA affects many young children in Africa. Current guidelines&#xD;
      do not recommend routine testing of hemoglobin in early infancy, as it is generally believed&#xD;
      that most infants are born with adequate iron stores to last 6 months. However, many African&#xD;
      infants are born with low iron stores and ID/IDA may develop earlier than generally&#xD;
      appreciated, within 2-3 months after birth. Vaccines provide tremendous benefits in LMIC;&#xD;
      however, they currently fail to reach their full potential. We need to better understand the&#xD;
      causes of vaccine failure, in order to develop new strategies to improve vaccine&#xD;
      immunogenicity. Despite lower efficacy in LMIC, these vaccines provide a major benefit&#xD;
      because the disease burden is so high; however, if approaches can be found to improve&#xD;
      immunogenicity, these vaccines would be even more powerful.&#xD;
&#xD;
      For this study, 6 weeks old infants will be randomly assigned to two study groups. Group 1&#xD;
      will receive iron at time of pediatric vaccinations from age 6-24 weeks. Group 2 will receive&#xD;
      no iron at time of pediatric vaccinations. All infants will receive a multivitamin syrup from&#xD;
      age 6-24 weeks. All infants remaining ID/IDA at age 24 weeks will receive iron. Infants will&#xD;
      be followed-up until age 52 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 7, 2021</start_date>
  <completion_date type="Anticipated">March 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Seroconversion</measure>
    <time_frame>6 weeks of age</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Seroconversion</measure>
    <time_frame>14 weeks of age</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Seroconversion</measure>
    <time_frame>24 weeks of age</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Seroconversion</measure>
    <time_frame>38 weeks of age</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Seroconversion</measure>
    <time_frame>52 weeks of age</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Antibody titers</measure>
    <time_frame>6 weeks of age</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Antibody titers</measure>
    <time_frame>14 weeks of age</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Antibody titers</measure>
    <time_frame>24 weeks of age</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Antibody titers</measure>
    <time_frame>38 weeks of age</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Antibody titers</measure>
    <time_frame>52 weeks of age</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Antibody avidity index</measure>
    <time_frame>6 weeks of age</time_frame>
    <description>percentage of antibodies that remain bound to beads</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Antibody avidity index</measure>
    <time_frame>14 weeks of age</time_frame>
    <description>percentage of antibodies that remain bound to beads</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Antibody avidity index</measure>
    <time_frame>24 weeks of age</time_frame>
    <description>percentage of antibodies that remain bound to beads</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Antibody avidity index</measure>
    <time_frame>38 weeks of age</time_frame>
    <description>percentage of antibodies that remain bound to beads</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Antibody avidity index</measure>
    <time_frame>52 weeks of age</time_frame>
    <description>percentage of antibodies that remain bound to beads</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>antiviral immunoglobulin G response</measure>
    <time_frame>6 weeks of age</time_frame>
    <description>Immunoassay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>antiviral immunoglobulin G response</measure>
    <time_frame>24 weeks of age</time_frame>
    <description>Immunoassay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>infant antiviral immunoglobulin G response</measure>
    <time_frame>52 weeks of age</time_frame>
    <description>Immunoassay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>immune cell populations</measure>
    <time_frame>6 weeks of age</time_frame>
    <description>number and type of immune cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>immune cell populations</measure>
    <time_frame>24 weeks of age</time_frame>
    <description>number and type of immune cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>immune cell populations</measure>
    <time_frame>52 weeks of age</time_frame>
    <description>number and type of immune cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proteomics</measure>
    <time_frame>6 weeks of age</time_frame>
    <description>Proteins involved in immune response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proteomics</measure>
    <time_frame>24 weeks of age</time_frame>
    <description>Proteins involved in immune response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proteomics</measure>
    <time_frame>52 weeks of age</time_frame>
    <description>Proteins involved in immune response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transcriptomics</measure>
    <time_frame>24 weeks of age</time_frame>
    <description>Genes involved in immune response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Human milk oligosaccharide secretor type</measure>
    <time_frame>14 weeks of age</time_frame>
    <description>secretor yes or no</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intestinal fatty acid binding protein</measure>
    <time_frame>6 weeks of age</time_frame>
    <description>Gut inflammation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intestinal fatty acid binding protein</measure>
    <time_frame>14 weeks of age</time_frame>
    <description>Gut inflammation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intestinal fatty acid binding protein</measure>
    <time_frame>24 weeks of age</time_frame>
    <description>Gut inflammation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Calprotectin</measure>
    <time_frame>6 weeks of age</time_frame>
    <description>Gut inflammation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Calprotectin</measure>
    <time_frame>14 weeks of age</time_frame>
    <description>Gut inflammation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Calprotectin</measure>
    <time_frame>24 weeks of age</time_frame>
    <description>Gut inflammation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin</measure>
    <time_frame>6 weeks of age</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin</measure>
    <time_frame>14 weeks of age</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin</measure>
    <time_frame>24 weeks of age</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin</measure>
    <time_frame>38 weeks of age</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin</measure>
    <time_frame>52 weeks of age</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Erythrocyte zinc protoporphyrin</measure>
    <time_frame>6 weeks of age</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Erythrocyte zinc protoporphyrin</measure>
    <time_frame>14 weeks of age</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Erythrocyte zinc protoporphyrin</measure>
    <time_frame>24 weeks of age</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Erythrocyte zinc protoporphyrin</measure>
    <time_frame>38 weeks of age</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Erythrocyte zinc protoporphyrin</measure>
    <time_frame>52 weeks of age</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum iron</measure>
    <time_frame>6 weeks of age</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum iron</measure>
    <time_frame>14 weeks of age</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum iron</measure>
    <time_frame>24 weeks of age</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum iron</measure>
    <time_frame>38 weeks of age</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum iron</measure>
    <time_frame>52 weeks of age</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma ferritin</measure>
    <time_frame>6 weeks of age</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma ferritin</measure>
    <time_frame>14 weeks of age</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma ferritin</measure>
    <time_frame>24 weeks of age</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma ferritin</measure>
    <time_frame>38 weeks of age</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma ferritin</measure>
    <time_frame>52 weeks of age</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transferrin receptor</measure>
    <time_frame>6 weeks of age</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transferrin receptor</measure>
    <time_frame>14 weeks of age</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transferrin receptor</measure>
    <time_frame>24 weeks of age</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transferrin receptor</measure>
    <time_frame>38 weeks of age</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transferrin receptor</measure>
    <time_frame>52 weeks of age</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-reactive protein</measure>
    <time_frame>6 weeks of age</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-reactive protein</measure>
    <time_frame>14 weeks of age</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-reactive protein</measure>
    <time_frame>24 weeks of age</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-reactive protein</measure>
    <time_frame>38 weeks of age</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-reactive protein</measure>
    <time_frame>52 weeks of age</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alpha-glycoprotein</measure>
    <time_frame>6 weeks of age</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alpha-glycoprotein</measure>
    <time_frame>14 weeks of age</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alpha-glycoprotein</measure>
    <time_frame>24 weeks of age</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alpha-glycoprotein</measure>
    <time_frame>38 weeks of age</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alpha-glycoprotein</measure>
    <time_frame>52 weeks of age</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intestinal fatty acid binding protein</measure>
    <time_frame>6 weeks of age</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intestinal fatty acid binding protein</measure>
    <time_frame>14 weeks of age</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intestinal fatty acid binding protein</measure>
    <time_frame>24 weeks of age</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intestinal fatty acid binding protein</measure>
    <time_frame>38 weeks of age</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intestinal fatty acid binding protein</measure>
    <time_frame>52 weeks of age</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">288</enrollment>
  <condition>Iron-deficiency</condition>
  <condition>Iron Deficiency Anemia</condition>
  <condition>Vaccination</condition>
  <condition>Pediatric ALL</condition>
  <arm_group>
    <arm_group_label>Immediate iron treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Iron and multivitamin syrup</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Delayed iron treatment</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Multivitamin syrup</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Iron syrup</intervention_name>
    <description>Daily supplementation with iron</description>
    <arm_group_label>Immediate iron treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Multivitamin syrup</intervention_name>
    <description>Daily supplementation with multivitamins</description>
    <arm_group_label>Delayed iron treatment</arm_group_label>
    <arm_group_label>Immediate iron treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Mother at least ≥15 years of age.&#xD;
&#xD;
          -  6 weeks (+/- 3 days) of age&#xD;
&#xD;
          -  Iron deficient (erythrocyte zinc protoporphyrin (ZnPP) &gt;61 μmol/mol heme)&#xD;
&#xD;
          -  With or without anemia, but not severely anemic (Hb &gt;70 g/L)&#xD;
&#xD;
          -  No malaria&#xD;
&#xD;
          -  No medical condition that precludes study involvement&#xD;
&#xD;
          -  Mother HIV negative&#xD;
&#xD;
          -  Vaginal delivery&#xD;
&#xD;
          -  No iron supplementation prior to study enrolment&#xD;
&#xD;
          -  Not wasted (length for height z score of ≥-2)&#xD;
&#xD;
          -  Not underweight (weight for age z score ≥-2)&#xD;
&#xD;
          -  From the hospital record, term or late preterm delivery (≥34 weeks)&#xD;
&#xD;
          -  Full-time breastfed at least until the screening&#xD;
&#xD;
          -  No vaccines beyond the birth dose of OPV and BCG prior to enrolment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>39 Days</minimum_age>
    <maximum_age>45 Days</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Nicole Stoffel, Dr.</last_name>
    <phone>+41 44 632 83 93</phone>
    <email>nicole.stoffel@hest.ethz.ch</email>
  </overall_contact>
  <location>
    <facility>
      <name>Msambweni County Referral Hospital</name>
      <address>
        <city>Msambweni</city>
        <state>Kwale</state>
        <country>Kenya</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kisia Samuel, MD</last_name>
      <phone>+254 722 232816</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Human Nutrition Laboratory ETH Zurich</name>
      <address>
        <city>Zürich</city>
        <zip>8092</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicole U Stoffel, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Kenya</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>January 28, 2021</study_first_submitted>
  <study_first_submitted_qc>February 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 9, 2021</study_first_posted>
  <last_update_submitted>February 16, 2021</last_update_submitted>
  <last_update_submitted_qc>February 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Swiss Federal Institute of Technology</investigator_affiliation>
    <investigator_full_name>Nicole Stoffel</investigator_full_name>
    <investigator_title>Dr. Nicole Stoffel</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Iron-Deficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

